- Trials with a EudraCT protocol (65)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (6)
65 result(s) found for: Myasthenia Gravis.
Displaying page 1 of 4.
EudraCT Number: 2018-002133-37 | Sponsor Protocol Number: ARGX-113-1705 | Start Date*: 2019-06-06 | |||||||||||||||||||||
Sponsor Name:argenx BVBA | |||||||||||||||||||||||
Full Title: A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of ARGX-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients with Myasthenia Gravis having Generalized... | |||||||||||||||||||||||
Medical condition: Myasthenia Gravis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Completed) CZ (Completed) DE (Completed) DK (Completed) BE (Completed) HU (Completed) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-000895-40 | Sponsor Protocol Number: BETA-MG-01 | Start Date*: 2019-03-28 | |||||||||||
Sponsor Name:Aarhus University Hospital | |||||||||||||
Full Title: Beta-agonist Efficacy and Tolerability as Adjuvant therapy in Myasthenia Gravis | |||||||||||||
Medical condition: Myasthenia Gravis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000460-21 | Sponsor Protocol Number: ALXN1720-MG-301 | Start Date*: 2022-10-21 | |||||||||||
Sponsor Name:Alexion Pharmaceuticals, Inc | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis. | |||||||||||||
Medical condition: Generalized Myasthenia Gravis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) DE (Ongoing) DK (Ongoing) IT (Ongoing) PL (Ongoing) AT (Ongoing) HU (Prematurely Ended) PT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001544-21 | Sponsor Protocol Number: MG2012PREP | Start Date*: 2012-11-07 | |||||||||||
Sponsor Name:Vall d'Hebron Institut de Recerca (VHIR) | |||||||||||||
Full Title: Intravenous immunoglobulin for preparing myasthenia gravis patients for thymectomy and other surgical procedures preventing myasthenic crisis. | |||||||||||||
Medical condition: Myasthenia gravis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004086-38 | Sponsor Protocol Number: ARGX-113-2002 | Start Date*: 2021-08-06 | |||||||||||
Sponsor Name:argenx BV | |||||||||||||
Full Title: A Long-Term, Single-Arm, Open-label, Multicenter Phase 3 Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Patients With Generalized Myast... | |||||||||||||
Medical condition: Generalized Myasthenia Gravis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) HU (Ongoing) BE (Ongoing) NL (Ongoing) IT (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003230-20 | Sponsor Protocol Number: MG0007 | Start Date*: 2020-11-30 | |||||||||||
Sponsor Name:UCB Biopharma SRL | |||||||||||||
Full Title: An Open-Label Extension Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis | |||||||||||||
Medical condition: Generalized myasthenia gravis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) CZ (Completed) FR (Completed) PL (Completed) HU (Completed) DK (Completed) BE (Completed) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000968-18 | Sponsor Protocol Number: MG0003 | Start Date*: 2019-09-06 | |||||||||||
Sponsor Name:UCB Biopharma SRL | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis. | |||||||||||||
Medical condition: Generalized myasthenia gravis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) GB (GB - no longer in EU/EEA) PL (Completed) DE (Completed) HU (Completed) CZ (Completed) BE (Completed) ES (Restarted) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002698-36 | Sponsor Protocol Number: MG0002 | Start Date*: 2017-02-09 | |||||||||||
Sponsor Name:UCB Biopharma SPRL | |||||||||||||
Full Title: A Multicenter, Randomized, Investigator- and Subject-Blind, Placebo-Controlled, Treatment Sequence Study Evaluating the Safety, Tolerability, and Efficacy of UCB7665 in Subjects with Moderate to Se... | |||||||||||||
Medical condition: Moderate to severe myasthenia gravis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) ES (Completed) CZ (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000596-34 | Sponsor Protocol Number: WX17798 | Start Date*: 2005-05-19 | |||||||||||
Sponsor Name:F.Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: A prospective, randomized, double-blind, placebo controlled, parallel group, multicenter, 36-weeks trial to assess the efficacy and safety of adjunct mycophenolate mofetil (MMF) to maintain or impr... | |||||||||||||
Medical condition: Myasthenia gravis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002817-37 | Sponsor Protocol Number: PIX200701 | Start Date*: 2008-07-29 | |||||||||||
Sponsor Name:ISTITUTO NEUROLOGICO "CARLO BESTA" | |||||||||||||
Full Title: A PHASE II, PLACEBO CONTROLLED, DOSE FINDING PILOT STUDY OF PIXANTRONE EFFICACY ADMINISTERED INTRAVENOUSLY IN PATIENTS AFFECTED WITH MYASTHENIA GRAVIS | |||||||||||||
Medical condition: Patients affected with MG showing clinically meaningful improvement after therapeutic plasmapheresis. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000343-28 | Sponsor Protocol Number: WX18411 | Start Date*: 2005-12-19 | |||||||||||
Sponsor Name:Aspreva Pharmaceuticals Corporation | |||||||||||||
Full Title: An optional continuation of double-blind treatment for subjects who have achieved good symptom control with stable prednisone dosing and who have completed Protocol WX17798 (A prospective, randomiz... | |||||||||||||
Medical condition: Myasthenia Gravis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004018-25 | Sponsor Protocol Number: MSK-002 | Start Date*: 2018-02-22 | |||||||||||
Sponsor Name:CATALYST PHARMACEUTICALS INC. | |||||||||||||
Full Title: A Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Amifampridine Phosphate in Patients with MuSK Antibody Positive Myasthenia Gravis, and a Sample of AChR Antibody Pos... | |||||||||||||
Medical condition: MuSK antibody positive myasthenia gravis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000969-21 | Sponsor Protocol Number: MG0004 | Start Date*: 2019-12-04 | |||||||||||
Sponsor Name:UCB Biopharma SPRL | |||||||||||||
Full Title: A Randomized, Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis | |||||||||||||
Medical condition: Generalized myasthenia gravis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) GB (GB - no longer in EU/EEA) DK (Completed) BE (Completed) DE (Completed) ES (Restarted) CZ (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005619-35 | Sponsor Protocol Number: REFINE2020 | Start Date*: 2021-06-07 | |||||||||||
Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE | |||||||||||||
Full Title: SINGLE-CELL DEEP PHENOTYPING OF B LYMPHOCYTES TO PERSONALIZE IMMUNOTHERAPY IN PATIENTS WITH MYASTHENIA GRAVIS: CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF RITXUXIMAB IN GENERALIZED ACHR-A... | |||||||||||||
Medical condition: Generalized AChR-antibody positive Myasthenia Gravis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000097-35 | Sponsor Protocol Number: CCFZ533X2204 | Start Date*: 2015-09-02 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multi-center, randomized, double-blind, placebo-controlled, parallel group study to preliminarily evaluate the safety, tolerability, pharmacokinetics and efficacy of CFZ533 in patients with moder... | |||||||||||||
Medical condition: Acquired myasthenia gravis (MG) is an autoimmune disease that leads to fluctuating muscle weakness and fatigue. In the most common cases, muscle weakness is caused by circulating antibodies that bi... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003870-21 | Sponsor Protocol Number: MG0020 | Start Date*: 2023-07-25 | |||||||||||
Sponsor Name:UCB Biopharma SRL | |||||||||||||
Full Title: An open-label, crossover study to evaluate rozanolixizumab self-administration by study participants with generalized Myasthenia Gravis | |||||||||||||
Medical condition: Generalized Myasthenia Gravis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001384-37 | Sponsor Protocol Number: ECU-MG-303 | Start Date*: 2020-10-07 | |||||||||||
Sponsor Name:Alexion Pharmaceuticals, Inc. | |||||||||||||
Full Title: An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Eculizumab in Pediatric Patients with Refractory Generalized Myasthenia Gravis (gMG) | |||||||||||||
Medical condition: Refractory Generalized Myasthenia Gravis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004777-14 | Sponsor Protocol Number: MSK-003 | Start Date*: 2018-06-05 | |||||||||||
Sponsor Name:CATALYST PHARMACEUTICALS INC. | |||||||||||||
Full Title: Long term safety study of amifampridine phosphate in patients with MuSK antibody positive and AChR antibody positive myasthenia gravis patients | |||||||||||||
Medical condition: MuSK antibody and AChR antibody positive myasthenia gravis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000323-27 | Sponsor Protocol Number: CV-0003 | Start Date*: 2017-08-03 | |||||||||||
Sponsor Name:CuraVac Europe SA | |||||||||||||
Full Title: A Multi-center, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Subcutaneous Injections of the Myasthenia Gravis Active Targeted Immunotherapy CV-MG0... | |||||||||||||
Medical condition: Myasthenia Gravis (MG) is a chronic neuromuscular disorder characterized by weakness and fatigability of skeletal muscles. The underlying defect is a decrease in the number of available acetylcho... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000949-14 | Sponsor Protocol Number: VIB0551.P3.S1 | Start Date*: 2020-11-16 | |||||||||||
Sponsor Name:Viela Bio, Inc. | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED PHASE 3 STUDY WITH OPEN-LABEL PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF INEBILIZUMAB IN ADULTS WITH MYASTHENIA GRAVIS | |||||||||||||
Medical condition: Myasthenia Gravis which is either due to acetylcholine receptor antibodies (AChR) or muscle specific kinase antibodies (MuSK). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) DK (Prematurely Ended) DE (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.